Clinical trials: Short Stature

Idiopathic Short Stature

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

• Completed
• Age: 3 to 10 years
• Phase 3
• Results posted

To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of…

Trial name

NCT00396097

Testing

Genotropin

Where

43 sites in United States

Volunteers

316 people

Sponsor

Pfizer